World’s Only Hygienic Digital Urine Test Launched
|
By LabMedica International staff writers Posted on 28 Jan 2019 |

Image: The Urine Testing System has been designed to improve the entire process from receiving the sample and recording results, to analysis in the laboratory (Photo courtesy of Clinical Design).
The world’s only hygienic, easy-to-use and accurate digital point-of-care urine test named Urine Testing System was launched at Arab Health 2019 by Clinical Design (Penryn, Cornwall, UK). The digital point-of-care urine test has been designed to improve the entire process from receiving the sample and recording results, to analysis in the laboratory.
The highly intuitive system features sealed, leak-proof samples, automatically timed readings and the ability to save digital results directly into the patient’s electronic health record. No decanting is required, reducing the risk of contamination and false positive samples being sent to laboratories. Digital readings are also more accurate compared to manual urinalysis as they eliminate variation in subjective analysis and the risk of error during manual recording.
Urine Testing System works seamlessly as a closed integrated system and includes a patented, single-use cap containing reagent pads to test ten parameters: leukocytes, nitrite, urobilinogen, protein, pH, blood, specific gravity, ketone, bilirubin and glucose. Once the patient has collected the urine sample, the healthcare professional simply connects UTS-10 Cap; creating a sealed, leak-proof module. This UTS module is then loaded into the UTS Digital Analyzer and the automatically timed, digital results are shown on the integrated LCD screen or in the UTS Desktop Software if connected to a computer.
The sample can be disposed of in clinical waste or be sent to the laboratory with no need to decant. It is specially designed to fit in standard laboratory racking – and can be purchased with or without boric acid depending on laboratory requirements. The current test takes approximately one to two minutes and risks include spillage of a contaminated sample, as well as human errors during analysis and/or the manual recording into a patient's records.
“We have developed a simple integrated system that increases the efficacy of patient point-of-care urine testing and improves first-time diagnosis. It is the only closed urine testing system available anywhere in the world and we are delighted to be able to showcase it at Arab Health 2019,” said Oliver Blackwell, CEO of Clinical Design.
Related Links:
Clinical Design
The highly intuitive system features sealed, leak-proof samples, automatically timed readings and the ability to save digital results directly into the patient’s electronic health record. No decanting is required, reducing the risk of contamination and false positive samples being sent to laboratories. Digital readings are also more accurate compared to manual urinalysis as they eliminate variation in subjective analysis and the risk of error during manual recording.
Urine Testing System works seamlessly as a closed integrated system and includes a patented, single-use cap containing reagent pads to test ten parameters: leukocytes, nitrite, urobilinogen, protein, pH, blood, specific gravity, ketone, bilirubin and glucose. Once the patient has collected the urine sample, the healthcare professional simply connects UTS-10 Cap; creating a sealed, leak-proof module. This UTS module is then loaded into the UTS Digital Analyzer and the automatically timed, digital results are shown on the integrated LCD screen or in the UTS Desktop Software if connected to a computer.
The sample can be disposed of in clinical waste or be sent to the laboratory with no need to decant. It is specially designed to fit in standard laboratory racking – and can be purchased with or without boric acid depending on laboratory requirements. The current test takes approximately one to two minutes and risks include spillage of a contaminated sample, as well as human errors during analysis and/or the manual recording into a patient's records.
“We have developed a simple integrated system that increases the efficacy of patient point-of-care urine testing and improves first-time diagnosis. It is the only closed urine testing system available anywhere in the world and we are delighted to be able to showcase it at Arab Health 2019,” said Oliver Blackwell, CEO of Clinical Design.
Related Links:
Clinical Design
Latest MEDLAB 2019 News
- ERBA Group Launches New Hematology Analyzers at MEDLAB 2019
- Telstar Promotes Latest Generation of Freeze Dryers in Dubai
- Siemens Healthineers Showcases In-Vitro Diagnostics Products at MedLab 2019
- Randox Promotes Evidence MultiSTAT Automated Benchtop Immunoassay Analyzer
- Mindray Displays New Generation Benchtop Cellular Analysis Line
- HORIBA Medical Shows Latest Yumizen G Range at Lab Trade Show
- Greiner Bio-One Displays Range of Safety Products at MedLab
- EKF Diagnostics Presents Latest Diabetes Care Analyzers
- BioSystems Highlights New iFOB Integral System at MedLab 2019
- Beckman Coulter Exhibits New Hematology Analyzer in Middle East
- Agappe Diagnostics Displays Analyzers and Solutions at Middle East Congress
- Abbott Highlights Point of Care Management Solutions
Channels
Clinical Chemistry
view channel
Daily Blood Biomarker Testing May Help Guide Earlier Antibiotic Stopping in Sepsis
Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read more
Blood Proteins Reveal Signals Linked to Prostate Cancer Risk Years Before Diagnosis
Prostate cancer is the most commonly diagnosed cancer in men worldwide. While many tumors grow slowly, aggressive forms can be life-threatening, underscoring the need for earlier risk identification.... Read more
Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment
Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more
Multimodal Platform to Combine Blood and Imaging Biomarkers for Lung Nodule Assessment
Lung nodules are commonly detected during chest imaging and require careful risk assessment to determine whether follow-up imaging, additional testing, or biopsy is needed. With millions of patients evaluated... Read moreMolecular Diagnostics
view channel
AI Tool Predicts Immunotherapy Response Using Tumor Senescence Signals
Patients receiving the same cancer immunotherapy can have markedly different outcomes, with some showing little or no response. Identifying these patients earlier could reduce the costs of ineffective... Read more
New Variant Tracking Option Expands Molecular Residual Disease Monitoring
Molecular residual disease (MRD) testing can detect traces of cancer that persist after treatment or emerge during recurrence. Because circulating tumor DNA (ctDNA) may be present at very low levels, residual... Read moreHematology
view channel
New Myelofibrosis Guidelines Recommend Expanded Genetic Testing at Diagnosis
Myelofibrosis is a rare, life-threatening blood cancer affecting up to six per 100,000 people. The disease causes scarring in the bone marrow, limiting the production of healthy blood cells and potentially... Read more
Handheld Point-of-Care Test Aims to Enable Rapid Coagulation Assessment in Trauma
Severe blood loss and inadequate tissue oxygenation are leading causes of preventable death after traumatic injury. Blood products are essential in trauma care, but cold-chain storage, short shelf life,... Read moreImmunology
view channel
Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more
Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more
Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk
A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more
Longitudinal Blood Testing Reveals Changes in Allergen Sensitization During Childhood
Food allergy is a major childhood health concern, and distinguishing persistent risk from transient sensitization can guide clinical decisions. Specific IgE antibodies may be detectable even when a child... Read moreMicrobiology
view channel
Molecular Panel Gains WHO Emergency Use Listing to Support Ebola Outbreak Response
The ongoing Ebola Bundibugyo outbreak in the Democratic Republic of the Congo and neighboring countries has become one of the largest outbreaks of this Ebola virus species recorded to date.... Read more
Rapid Host-Response Test Aims to Predict Corticosteroid Benefit in Sepsis
Sepsis and severe infections are difficult to treat because patients with similar clinical presentations may have very different underlying immune responses. Corticosteroids are commonly used in severe... Read morePathology
view channel
AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps
Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more
AI Pre-Screening Helps Identify Lung Cancer Cases for Additional Biomarker Testing
Tempus AI (Chicago, IL, USA) will present findings from a study evaluating an artificial intelligence (AI)-enabled pre-screening panel for advanced non-small cell lung cancer (NSCLC) at the ESMO Congress... Read more
AI Pathology Platform Targets Workflow Delays and Molecular Test Failures
Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more
Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
Barrett’s esophagus is a precancerous condition associated with increased risk of esophageal adenocarcinoma. Routine endoscopic biopsy findings guide surveillance and therapy, but histopathology may not... Read moreTechnology
view channel
New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows
Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read moreLaser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read moreIndustry
view channel
Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection
Cervical cancer is largely preventable with regular screening and early detection of human papillomavirus (HPV), the leading cause of the disease. Screening gaps persist, in part because traditional sample... Read more
Alzheimer’s Progression Blood Test Gains U.S. Patent Ahead of Planned Launch
Alzheimer’s disease is the most common cause of dementia, accounting for an estimated 60–70% of cases worldwide. Its progressive effects on memory, thinking, behavior, and daily functioning underscore... Read more








